Table 5.
Characteristics of Subjects with Autoantibody Testing versus Control Subjects Without Autoantibody Testing
| Characteristic | RF | ANA | ||
|---|---|---|---|---|
| Subjects with AutoAb Testing |
Subjects without AutoAb Testing |
Subjects with AutoAb Testing |
Subjects without AutoAb Testing |
|
| Number | 664 | 1259 | 772 | 1470 |
| Female, no. (%) | 457 (68.8%) | 868 (68.9%) | 539 (69.8%) | 1032 (70.2%) |
| Age at first test /index (mean ± s.d.), years | 50.0 ± 16.6 | 49.0 ± 16.5 | 47.8 ± 16.6 | 47.1 ± 16.6 |
| Length of Follow-up (mean ± s.d.), years | 9.7 ± 4.7 | 9.6 ± 4.7 | 9.5 ± 4.7 | 9.5 ± 4.8 |
|
Chronic disease comorbidities at time of testing/ index |
||||
| Diabetes Mellitus | 46 (6.9%) | 70 (5.6%) | 45 (5.8%) | 70 (4.8%) |
| Liver disease | 11 (1.7%) | 20 (1.6%) | 21 (2.7%) | 24 (1.6%) |
| Cerebrovascular disease | 45 (6.8%) | 75 (6.0%) | 52 (6.7%) | 68 (4.6%)* |
| Chronic pulmonary disease | 97 (14.6%) | 182 (14.5%) | 115 (14.9%) | 188 (12.8%) |
| Peptic Ulcer | 51 (7.7%) | 69 (5.5%) | 53 (6.9%) | 84 (5.7%) |
| Renal disease | 17 (2.6%) | 35 (2.8%) | 22 (2.8%) | 31 (2.1%) |
| Malignancy | 52 (7.8%) | 107 (8.5%) | 64 (8.3%) | 131 (8.9%) |
|
Patients who had rheumatic diseases (at time of testing /index or over time) |
||||
| Rheumatoid Arthritis, no. (%) | 80 (12.0%) | 40 (3.2%)** | 53 (6.9%) | 47 (3.2%)** |
| Systemic Lupus Erythematosus, no. (%) | 8 (1.2%) | 4/6 (0.5%) | 16 (2.1%) | 9 (0.6%)** |
| Polymyalgia Rheumatica, no. (%) | 21 (3.2%) | 17 (1.4%)** | 20 (2.6%) | 24 (1.6%) |
| Other Connective Tissue Disease, no. (%) | 12 (1.8%) | 3 (0.2%)** | 11 (1.4%) | 4 (0.3%)** |
RF = rheumatoid factor; ANA = antinuclear antibody
*
those with testing compared to those without testing p<0.01,
**
p<0.05